Parkwoods Wealth Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.01M Buy
2,513
+589
+31% +$602K 0.48% 36
2026
Q1
$1.77M Buy
1,924
+23
+1% +$23.3K 0.43% 32
2025
Q4
$2.04M Buy
1,901
+1,149
+153% +$1.1M 0.6% 27
2025
Q3
$574K Buy
752
+49
+7% +$36.5K 0.2% 47
2025
Q2
$548K Buy
703
+86
+14% +$66.8K 0.32% 25
2025
Q1
$510K Buy
617
+26
+4% +$21.6K 0.34% 21
2024
Q4
$456K Hold
591
0.36% 14
2024
Q3
$524K Buy
+591
New +$531K 0.43% 12

Other funds holding LLY

Parkwoods Wealth Partners's LLY Position: Q2 2026 in Review

Parkwoods Wealth Partners increased its Eli Lilly (LLY) stake by 31% in Q2 2026, buying an estimated $602K and bringing the position to 2,513 shares worth $3.01M. The position accounts for 0.48% of the portfolio, ranked #36.

Parkwoods Wealth Partners first reported a position in LLY in Q3 2024 and has held it in 8 quarters since. 4,630 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Parkwoods Wealth Partners held 2,513 shares of Eli Lilly worth $3.01M as of Q2 2026.
  • Parkwoods Wealth Partners bought 589 Eli Lilly shares in Q2 2026, an estimated $602K.
  • Eli Lilly made up 0.48% of Parkwoods Wealth Partners's portfolio in Q2 2026, its #36 holding.
  • Parkwoods Wealth Partners first reported a position in Eli Lilly in Q3 2024 and has held it in 8 quarters since.
  • 4,630 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Parkwoods Wealth Partners's 13F filing for Q2 2026, filed 27 Jul 2026.